{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:56:35Z","timestamp":1773273395185,"version":"3.50.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1097\/mnm.0b013e328358131f","type":"journal-article","created":{"date-parts":[[2012,8,10]],"date-time":"2012-08-10T07:12:00Z","timestamp":1344582720000},"page":"1144-1152","source":"Crossref","is-referenced-by-count":9,"title":["Semiautomated labelling and fractionation of yttrium-90 and lutetium-177 somatostatin analogues using disposable syringes and vials"],"prefix":"10.1097","volume":"33","author":[{"given":"Mattia","family":"Asti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Atti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Iori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Farioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelina","family":"Filice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annibale","family":"Versari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210212","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.2174\/138161209788682262","article-title":"Current status and perspectives in peptide receptor radiation therapy.","volume":"15","author":"Ansquer","year":"2009","journal-title":"Curr Pharm Des"},{"key":"R2-6-20210212","doi-asserted-by":"crossref","first-page":"42S","DOI":"10.2967\/jnumed.110.085753","article-title":"Radiopeptide imaging and therapy in Europe.","volume":"52","author":"Ambrosini","year":"2011","journal-title":"J Nucl Med"},{"key":"R3-6-20210212","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/cbr.2007.0435","article-title":"Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.","volume":"23","author":"De Visser","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"R4-6-20210212","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1021\/ar800188e","article-title":"Tumor imaging and therapy using radiolabeled somatostatin analogues.","volume":"42","author":"De Jong","year":"2009","journal-title":"Acc Chem Res"},{"key":"R5-6-20210212","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1677\/erc.1.01116","article-title":"Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.","volume":"12","author":"Kaltsas","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"R6-6-20210212","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/02841860701441848","article-title":"Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.","volume":"46","author":"Van Essen","year":"2007","journal-title":"Acta Oncol"},{"key":"R7-6-20210212","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/MNM.0b013e328318effb","article-title":"Radiation protection in 90Y-labelled DOTA-D-Phe1-Tyr3-octreotide preparations.","volume":"30","author":"Grassi","year":"2009","journal-title":"Nucl Med Commun"},{"key":"R8-6-20210212","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/MNM.0b013e328349fd60","article-title":"Personnel exposure in labelling and administration of 177Lu-DOTA-D-Phe1-Tyr3-octreotide.","volume":"32","author":"Sghedoni","year":"2011","journal-title":"Nucl Med Commun"},{"key":"R9-6-20210212","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/MNM.0b013e3283497188","article-title":"Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system.","volume":"32","author":"Petrik","year":"2011","journal-title":"Nucl Med Commun"},{"key":"R10-6-20210212","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/MNM.0b013e3283348771","article-title":"Automated radiolabelling of monoclonal antibodies with the Modular Lab system.","volume":"31","author":"Ellison","year":"2010","journal-title":"Nucl Med Commun"},{"key":"R11-6-20210212","first-page":"1384","article-title":"Prevention of radiolysis of monoclonal antibody during labelling.","volume":"37","author":"Chakrabarti","year":"1996","journal-title":"J Nucl Med"},{"key":"R12-6-20210212","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.apradiso.2008.08.015","article-title":"Studies into radiolytic decomposition of fluorine-18 labeled radiopharmaceuticals for positron emission tomography.","volume":"67","author":"Scott","year":"2009","journal-title":"Appl Radiat Isot"},{"key":"R13-6-20210212","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/rpd\/ncl384","article-title":"Beta radiation exposure of medical staff and implications for extremity dose monitoring.","volume":"125","author":"Rimpler","year":"2007","journal-title":"Radiat Prot Dosimetry"},{"issue":"1-4","key":"R14-6-20210212","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/rpd\/ncq574","article-title":"Extremity exposure in nuclear medicine: preliminary results of a European study.","volume":"144","author":"Sans Merce","year":"2011","journal-title":"Radiat Prot Dosimetry"},{"key":"R15-6-20210212","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0969-8043(03)00170-2","article-title":"Automated preparation of 188Re-labeled radiopharmaceuticals for endovascular radiation therapy.","volume":"59","author":"Oh","year":"2003","journal-title":"Appl Radiat Isot"},{"key":"R16-6-20210212","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.apradiso.2010.11.001","article-title":"Automation of labelling of lipiodol with high-activity generator-produced 188Re.","volume":"69","author":"Lapareur","year":"2011","journal-title":"Appl Radiat Isot"},{"key":"R17-6-20210212","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.nucmedbio.2011.10.015","article-title":"Influence of cations on complexation yield of DOTATATE with yttrium and lutetium: a perspective study for enhancing the 90Y and 177Lu labeling conditions.","volume":"39","author":"Asti","year":"2012","journal-title":"Nucl Med Biol"},{"key":"R18-6-20210212","first-page":"1467","article-title":"Dosimetry in peptide radionuclide receptor therapy: a review.","volume":"47","author":"Cremonesi","year":"2006","journal-title":"J Nucl Med"},{"key":"R19-6-20210212","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.nucmedbio.2004.03.008","article-title":"Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in 90Y-DOTA0,Tyr3octreotide solutions containing free 90Y3.","volume":"31","author":"Breeman","year":"2004","journal-title":"Nucl Med Biol"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006231-201211000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:49:39Z","timestamp":1618037379000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006231-201211000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0b013e328358131f","relation":{},"ISSN":["0143-3636"],"issn-type":[{"value":"0143-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}